Recombinant *Lactococcus lactis* NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells

Bo Zhang¹,², Angdi Li², Fanglei Zuo², Rui Yu¹,², Zhu Zeng¹,², Huiqin Ma³ and Shangwu Chen¹,²*

**Abstract**

**Background**: Proteinaceous bioactive substances and pharmaceuticals are most conveniently administered orally. However, the facing problems are the side effects of proteolytic degradation and denaturation in the gastrointestinal tract. In recent years, lactic acid bacteria (LAB) have been verified to be a promising delivery vector for susceptible functional proteins and drugs. KiSS-1 peptide, a cancer suppressor, plays a critical role in inhibiting cancer metastasis and its activity has been confirmed by direct administration. However, whether this peptide can be functionally expressed in LAB and exert activity on cancer cells, thus providing a potential alternative administration manner in the future, has not been demonstrated.

**Results**: A recombinant *Lactococcus lactis* strain NZ9000-401-kiss1 harboring a plasmid containing the gene of the tumor metastasis-inhibiting peptide KiSS1 was constructed. After optimization of the nisin induction conditions, the recombinant strain efficiently secreted KiSS1 with a maximum detectable amount of 27.9 μg/ml in Dulbecco’s Modified Eagle medium. The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide and wound healing assays, respectively, indicated that the secreted KiSS1 peptide remarkably inhibited HT-29 cell proliferation and migration. Furthermore, the expressed KiSS1 was shown to induce HT-29 cell morphological changes, apoptosis and reduce the expression of matrix metalloproteinase 9 (MMP-9) at both mRNA and protein levels.

**Conclusions**: A recombinant *L. lactis* NZ9000-401-kiss1 successfully expressing the human kiss1 was constructed. The secreted KiSS1 peptide inhibited human HT-29 cells’ proliferation and migration probably by invoking, or mediating the cell-apoptosis pathway and by down regulating MMP-9 expression, respectively. Our results suggest that *L. lactis* is an ideal cell factory for secretory expression of tumor metastasis-inhibiting peptide KiSS1, and the KiSS1-producing *L. lactis* strain may serve as a new tool for cancer therapy in the future.

**Keywords**: *Lactococcus lactis*, KiSS1, Functional protein, Delivery vector

**Background**

Oral administration employing delivery systems like hydrogels, nanoparticles, microspheres, and lipid-based systems is a convenient way of delivering drugs. However, this strategy usually has poor efficiency for bioactive macromolecules such as peptides and proteins due to the harsh gastrointestinal environment, with proteolysis resulting in denaturation and degradation of susceptible components [1]. Strategies for the delivery of proteinaceous agents have been intensively explored [2–4] to reduce the burden of repeat dosages and increased cost to improve the therapeutic effect. Potential alternative route might be using living microorganisms or other improved physically coated delivery vectors [4, 5].
Lactic acid bacteria (LAB) are generally regarded as safe for human health. In the last two decades, the feasibility of using LAB as functional protein delivery vectors has been widely investigated [6]. Lactococcus lactis, a LAB model species, has been demonstrated to be a promising candidate for the delivery of functional proteins, mainly because this bacterium is a noninvasive and nonpathogenic organism with fewer secretary proteins and extracellular proteases produced [7]. Many different expression systems of L. lactis have been developed and used for heterologous protein expression [8–10]. The most commonly used system is the nisin-controlled gene expression (NICE) system, containing the nisin promoter [8]. Some successful examples using L. lactis as a functional protein-delivery vector have been reported [10–12]. In particular, use of an interleukin-10-secreting L. lactis to treat Crohn’s disease has passed phase 1 clinical trials [13], indicating that L. lactis is indeed a safe mucosal vector for functional protein delivery. Tumor-targeted reagents, anticancer drugs, and non-invasive insulin- and vaccine-delivery systems can be developed based on live L. lactis [14, 15].

Nowadays, in cancer research, more attentions have been paid on the blockade of the metastatic process at the early stage [16]. Therefore, there is growing interest in identifying metastasis suppressor genes, which may be involved in the anti-metastatic activity. Kisspeptins (KiSS1) are peptide products of the kiss1 gene, which was first identified by Lee et al. [17] in 1996 as a suppressor of tumor metastasis in human malignant melanoma cells. Gene kiss1 is predicted to encode a 145-amino-acid peptide that can be cleaved into smaller peptides, known as kisspeptin-54 (KP54), KP14, KP13, and KP10. KiSS1 has been studied in various types of cancer and has been suggested to play multiple roles in cancer development and in suppression of metastasis, such as thyroid cancer, oesophageal carcinoma, urinary bladder cancer, gastric carcinoma, epithelial ovarian cancer, and colorectal cancer [18–23]. These studies provided numerous experimental and clinical evidences that KiSS1 could be a potential molecular target for treatment of metastasis during cancer progression.

Some of previous studies used synthetic or purified KiSS1 form tissue to investigate the anti-tumor effect of KiSS1 on cancer cells [24–27], while others applied transfection method (using expression vector containing kiss1 gene) to introduce KiSS1 into the tumor cells [28]. However, limited information is available with respect to the development of new strategies for delivering this proteinaceous anti-tumor molecule for therapeutic purpose in the future.

In this study, we evaluated whether L. lactis can be used as a cell factory to produce bioactive KiSS1 peptide and whether the secreted product has anti-tumor activity using the human colon cancer HT-29 as a model for in vitro experiments. Our results provide foundations for future exploitation of recombinant LAB for in vivo delivery of the proteinaceous agent KiSS1 in cancer therapy.

Results

Cloning and expression of kiss1 in L. lactis NZ9000

The whole kiss1 gene in length of 417 bp was amplified from the cDNA of human placenta by PCR and cloned into the nisin-induction vector pNZ401 which contained the Usp45 signal peptide and LEISSTCDA [29] synthetic propeptide (Fig. 1a). The resulting recombinant plasmids pNZ401 and pNZ401-kiss1 were transformed into L. lactis NZ9000, respectively. After induction with 10 ng/ml nisin for 1 h, the total cell protein and the secreted protein in the culture supernatant were separately extracted. Western blotting assay using anti-KiSS1 antibody revealed the expected 14.8-kD protein product in both the total protein extract and the extracellular protein extract from the recombinant strain harboring pNZ401-kiss1 (designated L. lactis NZ9000-pNZ401-kiss1) (Fig. 1b); however, no KiSS1 band was found in the parent strain (NZ9000) harboring the empty vector pNZ401 (designated L. lactis NZ9000-pNZ401), suggesting that kiss1 was successfully expressed in L. lactis NZ9000.

Optimization of expression conditions and detection of KiSS1 secretion

To optimize the expression of the recombinant protein, different induction time (at the nisin concentration of
10 ng/ml) was tested. At each induction conditions, the amount of protein expressed was determined by indirect competitive enzyme-linked immunosorbent assay (ELISA). The results showed that KiSS1 production increased to a maximum detectable concentration of 18.7 μg/ml after 3–5 h induction (Fig. 2), and decreased thereafter. Thus the optimal condition for KiSS1 secretion was determined to be induction for 3 h with 10 ng/ml nisin.

For the cell experiments, conditioned Dulbecco's Modified Eagle medium (DMEM) was used to determine KiSS1 secretion. The recombinant strain *L. lactis* NZ9000-pNZ401-kiss1 as well as the control strain were cultured to an OD600 of 0.4, and then resuspended at different cell densities (5 × 10⁸ and 5 × 10⁹ CFU/ml) in DMEM before nisin addition. To determine the secretion of KiSS1, western blotting was performed to detect KiSS1 in the DMEM (Fig. 3a) and quantitative analysis was performed by indirect competitive ELISA (Fig. 3b). The results showed that the level of secreted KiSS1 was positively correlated with bacterial cell density; the maximal detected KiSS1 levels were 19.7 and 27.9 μg/ml in the *L. lactis* NZ9000-pNZ401-kiss1-conditioned DMEM at 5 × 10⁸ and 5 × 10⁹ CFU/ml cell densities, respectively. No corresponding products were found in the control strain *L. lactis* NZ9000-pNZ401 harboring empty vector. In addition, no detectable leaky expression of KiSS1 from the *L. lactis* NZ9000-pNZ401-kiss1 strain was observed (Fig. 3a), indicating that the PnisA promoter was highly efficient and fully functional for the induction of KiSS1 expression by nisin. Taken together, these results confirmed that KiSS1 is successfully heterogeneously expressed in the recombinant *L. lactis* NZ9000-pNZ401-kiss1 and effectively secreted into DMEM using 10 ng/ml nisin.

**L.lactis** KiSS1 inhibits HT-29 cell proliferation and migration

To evaluate whether the secreted KiSS1 was biologically active, we first tested the inhibition effect of KiSS1 on HT-29 cell proliferation using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. The results showed that both the supernatant of DMEM conditioned with *L. lactis* NZ9000 and NZ9000-pNZ401 strains inhibited HT-29 cell proliferation; however, the rate of HT-29-growth inhibition by KiSS1 in recombinant *L. lactis* NZ9000-pNZ401-kiss1-conditioned DMEM was 2.52-fold (24 h) and 2.24-fold (48 h) higher (P ≤ 0.001) than that in *L. lactis* NZ9000-pNZ401-conditioned DMEM at those time points (Fig. 4). The total inhibition of HT-29 cell proliferation reached 54.2 % (24 h) and
69.1 % (48 h) by KiSS1. Thus the *L. lactis*-secreted KiSS1 was correctly processed, functionally folded and actively involved in inhibition of HT-29 cell proliferation. We further investigated the HT-29 cell migration in monolayer culture under different treatments (Fig. 5). HT-29 cells were firstly seeded on fibronectin-coated 6-well culture plates. After 24-h culture, cell monolayers were wounded and the culture medium was replaced by DMEM with or without KiSS1. After another 24-h culture, the results showed that, in the KiSS1-conditioned medium, the migration rate of HT-29 cells was only 44.5 % of that in KiSS1-negative medium (*P ≤ 0.01), indicating that the *L. lactis*- secreted KiSS1 effectively inhibits HT-29 migration.

**KiSS1 induces cell morphological changes, apoptosis and a decrease of MMP-9 expression**

The morphological changes of HT-29 cells cultured in *L. lactis* NZ9000-pNZ401-kiss1-conditioned DMEM displayed typical features of cell apoptosis/programmed cell death, i.e., various degrees of shrinkage, blebbing, aggregation and lack of obvious boundaries (Fig. 6), whereas cells growing in only DMEM or in *L. lactis* NZ9000-pNZ401-conditioned DMEM developed with clear, regular boundaries (Fig. 6a–c).

To further confirm KiSS1 induction of cell apoptosis, analytical flow cytometry with Annexin V-PI (propidium iodide) double staining was used to assay the changes in HT-29 cells (Fig. 7). The apoptosis-inducing effect was observed in HT-29 cells at different cell cycle stages, mostly at the late stage of the cell cycle. The KiSS1-negative controls *L. lactis* NZ9000 and *L. lactis* NZ9000-pNZ401 and the KiSS1-positive *L. lactis* NZ9000-pNZ401-kiss1 all induced constitutive apoptosis, at a rate of 13.26, 19.18 and 37.63 % of total cells, respectively (Fig. 7a–c). However, the apoptotic rate induced by the KiSS1-positive *L. lactis* NZ9000-pNZ401-kiss1 was 1.96-fold (*P ≤ 0.001) and 2.8-fold (*P ≤ 0.001) of that by *L. lactis* NZ9000-pNZ401 and *L. lactis* NZ9000, respectively. These results confirmed that KiSS1 secreted by *L. lactis* has apoptosis-inducing effects on the HT-29 cell. Therefore, we infer that the inhibition of HT-29 cell
Fig. 6 Photomicrographs of HT-29 cells treated with KiSS1 for 24 h. a Nontreated control. b Cells treated with L. lactis NZ9000-pNZ401. c Cells treated with L. lactis NZ9000-pNZ401-kiss1. Red arrow indicates apoptotic cell. Magnification 250x.

Fig. 7 Effect of KiSS1 on HT-29 cell apoptosis. a Nontreated control. b Cells treated with L. lactis NZ9000-pNZ401. c Cells treated with L. lactis NZ9000-pNZ401-kiss1. d Percentage of apoptotic cells induced by KiSS1. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Quadrant 2 (upper right) and quadrant 4 (lower right) in panels a, b and c indicate late and early apoptotic cells, respectively.
proliferation by KiSS1 from *L. lactis* is probably through invoking, or mediating the cell-apoptosis pathway.

Previous studies have shown that the expression level of matrix metalloproteinase 9 (MMP-9) is important for tumor cell invasion, migration and metastasis [29]. To examine whether KiSS1 affects MMP-9 expression, MMP-9 gene transcription and protein expression in HT-29 cells under the different treatments, with or without KiSS1-conditioned medium, were assayed (Fig. 8). Both the intensities of MMP-9 mRNA and protein bands in the cells treated with *L. lactis* NZ9000-secreted KiSS1 were lower than in the other two groups (no treatment and *L. lactis* NZ9000 harboring pNZ401 vector). As shown in Fig. 8c, the relative expression level of MMP-9 protein in the KiSS1 group decreased 3.75-fold compared to *L. lactis* NZ9000 harboring pNZ401 vector (*P* ≤ 0.001), suggesting that the expression of MMP-9 in HT-29 cells was downregulated by the *L. lactis* NZ9000-secreted KiSS1, thus exerting the inhibition effects on cell proliferation and migration.

KiSS1 downregulates MMP-9 expression through G-protein coupled receptor 54 (GPR54) and activated ERK-MAPK signaling pathway

It is reported that the downregulation of MMP-9 via GPR54 and ERK-MAPK signaling pathway was involved in the inhibitory effect of KiSS1 on the migration and invasion of cancer cells [30, 31]. To confirm this and to investigate the specificity of KiSS-1 action, kisspeptin 234 (GPR54 inhibitor), a 10-amino acid peptide antagonist for the kisspeptin-1/GPR-54 signaling system, was used in the inhibition experiments and the expression levels of Phosphor-Erk1/2 (ERK-MAPK pathway) and MMP-9 were evaluated. As shown in Fig. 9, KiSS1 expressed in *L. lactis* NZ9000-kiss1 obviously activated the expression of Phosphor-Erk1/2 and reduced the expression of MMP-9. On the contrary, when the inhibitor, kisspeptin 234, was added, the expression of Phosphor-Erk1/2 was significantly inhibited while the expression of MMP-9 was reversed. These results indicated that KiSS1 expressed in *L. lactis* effectively downregulated the expression of MMP-9 through the previously reported G-protein coupled receptor 54 and the activated ERK-MAPK signaling pathway.

**Discussion**

The safety and efficacy of the food-grade microorganism *L. lactis* as oral vectors for mucosal delivery has been widely confirmed [6, 14]. Bioactive molecules delivered by this bacterium for therapeutic purpose (using both in vitro and in vivo models) includes anti-TNFα nanobodies for treatment of inflammatory bowel disease (IBD), glucagon like peptide-1 (GLP-1) for type 2 diabetes, leptin for body weight control, HPV-16 E7 protein for cervical cancer, catalase for IBD/colorectal cancer, among others [14]. In this

![Fig. 8](image-url)
study, we further verified that *L. lactis* was an excellent candidate as a delivery vector that can be engineered to secrete the anti-cancer peptide KiSS1 using the nisin-inducible expression system. In addition, it was demonstrated that tumor growth can be inhibited by the LAB strain itself [32, 33] due to the LAB’s ability to produce exopolysaccharides [34, 35], which is also an attractive feature for using *L. lactis* to deliver anti-cancer bioactive protein. We also observed that, as shown in Figs. 4 and 6, the control groups (*L. lactis* NZ9000 and *L. lactis* NZ9000-pNZ401) can inhibit HT-29 proliferation and induce cell apoptosis.

KiSS1 and its receptor KiSS1R have been studied for their metastasis-suppressing ability in numerous human cancer cells [20, 22, 24]. For example, it is found that high expression of KiSS1 can inhibit proliferation and invasion of tumor cells via lipofectin transfection of expression vector containing full-length KiSS1 complementary DNA (cDNA) into the tumor cell [28]. KP10, a short 10-amino acid peptide of KiSS1, can also inhibit proliferation and migration of tumor cells in vitro and in vivo [25, 36, 37]. We therefore hypothesized that expression of biologically active KiSS1 would inhibit proliferation and migration of different kinds of cancer cells. As an example shown here, *L. lactis* NZ9000 was demonstrated to be a cell factory for the secretion of biologically active KiSS1 protein, exerting inhibition effects on human colorectal cancer HT-29 cells. Matrix metalloproteinases (MMPs) play crucial roles in invasion, metastasis and regulation of the signaling pathways controlling tumor cell growth, survival, invasion, inflammation and angiogenesis [38–40]. MMP-9 can release factors sequestered in the extracellular matrix, including VEGF, TGF-β and FGF-2, and stimulate proliferation and migration of endothelial cells [38, 41]. It is evident that KiSS-1 can suppress MMP-9 expression [42]; we therefore tested whether our expressed protein had such activity. The results firmly confirmed that KiSS1 secreted from our recombinant *L. lactis* NZ9000-pNZ401-KiSS1 strain effectively downregulated the expression of MMP-9. The reason for this is that KiSS1 is known to activate the MAPK pathway via GPR54 signaling, suppressing NFκB binding to the MMP-9 promoter and thus downregulating MMP-9 expression [31]. This, in turn, reduces the survival rate, inhibits metastasis and induces dormancy of cancer cells. Here, by using GPR54 inhibitor, we further confirmed that KiSS1 expressed in *L. lactis* can effectively downregulate the expression of MMP-9 via GPR54 and the ERK-MAPK signaling pathway. These results were in accordance with previous findings for KiSS1 [43–45], warranting further exploration of the effectiveness of KiSS1-secreting *L. lactis* in vivo at inducing apoptosis, and inhibiting cell proliferation and metastasis.

**Conclusions**

The human tumor-metastasis inhibitor protein KiSS1 was successfully expressed in *L. lactis*. The secreted KiSS1 remarkably inhibited human colonic epithelial HT-29 cell proliferation and migration mainly by inducing apoptosis and inhibiting MMP-9 expression, respectively. To our knowledge, this is the first time that the biologically active KiSS1 protein was successfully expressed in *L. lactis* and the anti-cancer effects of the secreted protein were evaluated. Our study suggests that *L. lactis* is an ideal vector for the secretion expression of anti-cancer agent KiSS1, which maybe a promising strategy for cancer therapy in the future.

**Methods**

**Bacterial strains and growth conditions**

The strains and plasmids used in this study are listed in Table 1. *L. lactis* NZ9000 was cultured in M17 (Difco) containing 0.5 % (w/v) glucose at 30 °C without shaking. To culture recombinant *L. lactis* strains, erythromycin was added at 5 μg/ml. *Escherichia coli* was incubated in LB medium at 37 °C with shaking at 220 rpm for 16 h.

**Gene cloning, plasmid construction, and heterologous expression and secretion of KiSS1 by *L. lactis* NZ9000**

The primers used in this study are listed in Table 2. Plasmid preparation, restriction endonuclease digestion, DNA ligation and other recombinant DNA techniques were performed according to standard methods.
[47]. The PCR product of *Homo sapiens* KiSS-1 metastasis-suppressor cDNA (GenBank accession number BC022819.1) was cloned into plasmid pNZ401, resulting in pNZ401-kiss1. Plasmids pNZ401-kiss1 and empty control pNZ401 extracted from *E. coli* DH5α were both transformed into *L. lactis* NZ9000. For inducible expression, the recombinant *L. lactis* NZ9000-pNZ401-kiss1 and control (NZ9000-pNZ401) transformants were grown overnight in glucose-M17 (GM17) medium containing 5 µg/ml erythromycin. A 2 % (v/v) inoculum of the *L. lactis* strains was transferred to fresh GM17 broth and grown at 30 °C without shaking to an optical density at 600 nm (OD 600) of 0.4–0.6, and then 10 ng/ml nisin (50 IU/ml, Sigma) was added and the mixture was incubated for 3 h. The mixture was centrifuged and the supernatant was collected, neutralized with sodium hydroxide and filtered through a 0.22-µm membrane as DMEM-KiSS1 conditioned media. Fetal calf serum (10 % v/v) was added for incubation with HT-29 cells.

Western blot analysis and ELISA quantification of KiSS1

The induced recombinant *L. lactis* was harvested by centrifugation at 8000g for 10 min at 4 °C. Pelleted cells were washed three times in PBS, resuspended in PBS and disrupted by ultrasonicator. The supernatants were placed in fresh tubes and mixed with trichloroacetic acid at a ratio of 1:9 (v/v), and allowed to precipitate for 2 h at 4 °C. Then the mixture was centrifuged at 10,000g for 15 min at 4 °C. The liquid was discarded and the pellet was washed three times in ice-cold acetone. Finally, the pellets were air-dried and dissolved in PBS buffer. Each protein sample was mixed with 5 × SDS loading buffer (250 mM Tris–HCl pH 6.8, 10 % w/v SDS, 0.5 % w/v bromophenol blue, 50 % w/v glycerol, 5 % w/v β-mercaptoethanol) and separated by 12 % SDS–PAGE, and then transferred to a nitrocellulose membrane using a semi-dry transmembrane system. Protein bands were detected using anti-KiSS1 rabbit monoclonal antibody (Santa Cruz Biotechnology). *L. lactis* NZ9000-pNZ401 (harboring empty vector pNZ401) was used as a control.

The concentration of the secreted KiSS1 was estimated by indirect competitive ELISA. Microtiter plates with 96 wells were coated with 100 µl antigen per well diluted in 50 mmol/l carbonate buffer (pH 9.8) to a concentration of 10 µg/ml and incubated overnight at 4 °C. Sample solutions and standard antigen (KiSS1 protein, Sigma) were respectively incubated overnight at 4 °C with an equivalent volume of anti-KiSS1 antibody, diluted 1:400 in 10 mmol/l PBS (pH 7.4) containing 10 g/l bovine

### Table 1 Bacterial strains and plasmids used in this study

| Strains/plasmids | Relevant characteristics | Source or references |
|------------------|-------------------------|----------------------|
| *Lactococcus lactis* NZ9000 | MG1363 pepN:nisRK | [46] |
| *L. lactis* NZ9000-pNZ401 | *L. lactis* NZ9000 harboring empty vector pNZ401 | This study |
| *L. lactis* NZ9000-pNZ401-kiss1 | *L. lactis* NZ9000 harboring pNZ401-kiss1 | This study |
| *Escherichia coli* DH5α | Cloning host | Takara |
| *E. coli* DH5α-pNZ401 | *E. coli* DH5α harboring empty vector pNZ401 | Laboratory stock |
| *E. coli* DH5α-pNZ401-kiss1 | *E. coli* DH5α harboring pNZ401-kiss1 | This study |
| pNZ401 | Em', inducible expression vector containing the nisA promoter, derivative of pNZ8048 | Laboratory stock |
| pNZ401-kiss1 | pNZ401 carrying kiss1 gene | This study |

### Table 2 Primers used in this study

| Primer | Sequence (5' → 3') | Description and location |
|--------|-------------------|-------------------------|
| Primer 1 | ATCCATGGGATGAAAAAAAAGATTA | Upstream of SPP2-F, NcoI |
| Primer 2 | CATGCGATCCTGCGTCACAAGTCGAGGATA | Downstream of SPP2-R, SphI |
| Primer 3 | CATGCGATCAAGACTCACTGGTTTCCTT | Upstream of kiss1-F, SphI |
| Primer 4 | CCCAAGCTTCAGCCCCGCCCAGGCTTC | Downstream of kiss1-R, HindIII |
| Primer 5 | ACCACAGTCCATGCGCATCAC | Upstream of GAPDH for RT-PCR |
| Primer 6 | TCCACCACTCTTGTGTGTGA | Downstream of GAPDH for RT-PCR |
| Primer 7 | GTGGGAATCGATGTCCC | Upstream of MMP-9 for RT-PCR |
| Primer 8 | GCCCACAATCTCTCCCA | Downstream of MMP-9 for RT-PCR |

a The added restriction enzyme sites are underlined
b SPP2 includes Usp45 signal peptide and LEISSTCDA synthetic propeptide
c *Homo sapiens* KiSS-1 metastasis suppressor: gb:BC022819.1 (cDNA clone MGC:39258 IMAGE:5443510)
serum albumin (BSA) and 1 g/l Tween 20 (PBS-BSA-T). The plates were washed four times the next day with 250 µl per well of 10 mmol/l PBS (pH 7.4) containing 0.5 g/l Tween 20 (PBS-T). After washing the plates, the wells were filled with 100 µl PBS-BSA-T per well to block residual free binding sites and incubated for 1 h at 37 °C. The plates were washed and then 100 µl per well of reactive mixtures of samples or standard antigen and antibodies were added and incubated for 1 h at 37 °C. After washing the plates, the wells were filled with 100 µl per well horseradish peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology), diluted 1:20,000 in PBS-BSA-T. After incubation for 1 h at 37 °C, the plates were washed again and then 100 µl per well of 3,3′,5,5′-tetramethylbenzidine (TMB, Amresco) substrate solution was immediately added. The plates were incubated for 15 min at 37 °C. Finally, 50 µl per well of 2 mol/l H2SO4 was added to stop the reaction. Absorption was determined at the dual wavelengths of 450 nm and 630 nm by Multiskan MK3 ELISA plate reader (Thermo Labsystems). PBS-BSA-T without anti-KiSS1 antibody was included as the blank, and PBS-BSA-T without sample was the control.

**HT-29 cell culture and assays**

Human colonic epithelial HT-29 cells (ATCC HTB 38) were cultured in DMEM containing 10 % fetal calf serum, and 100 U/ml penicillin/streptomycin. Cell proliferation was analyzed by MTT assay. HT-29 cells were seeded in 96-well plates at a density of 10^5 cells per well with DMEM containing 10 % fetal calf serum. After 24 h incubation, the medium was discarded and changed to DMEM-KiSS1 conditioned medium (100 µl per well). Cells were treated at 24 and 48 h. Medium was removed and then incubated with 100 µl MTT solution (0.5 mg/ml) for 4 h. The MTT is converted to blue formazan, which was then dissolved in 200 µl DMSO and the sample was read in a Multiskan MK3 plate reader (Thermo Labsystems). Absorption was determined at 540 nm. The MTT assay is based on the fact that the MTT can be converted into formazan crystals by viable cells, which determines mitochondrial activity. In cell populations, the total mitochondrial activity is related to the number of living cells. Therefore, MTT assay can be used to measure the in vitro inhibition effect of drugs on cell proliferation [48].

**Detection of apoptosis by flow cytometry**

HT-29 cells were inoculated at 5 × 10^5 cells per well in 6-well plates. After incubation for 12 h, the cells were attached to the plates. The medium was then discarded and replaced with DMEM-KiSS1 conditioned medium (2 ml per well) incubating for 24 h. HT-29 cells cultured in DMEM alone and in L. lactis NZ9000-401-conditioned DMEM were used as controls. Cells were then treated with Annexin V-PI (propidium iodide) cell apoptosis kit (Biyuntian Biotech Co. Ltd.). Apoptosis was detected by flow cytometry using a FACScan (Becton–Dickinson).

**Wound-healing assay**

HT-29 cells were seeded on fibronectin (40 µg/ml)-coated 6-well culture plates at a density of 10^6 per well. After 24 h culture, cell monolayers were wounded with a pipette tip and washed with PBS. The culture medium was discarded and replaced with DMEM containing 1 % fetal calf serum with or without KiSS1 (27.9 µg/ml, 1 ml per well). Cells were grown for 24 h, and those migrating toward the wound regions were imaged and counted. The detail experimental procedures were performed according to previously described protocol [49].

**HT-29 cell RNA and protein extraction**

Total RNA from HT-29 cells was isolated using TRIzol Reagent (Invitrogen), and then treated with RNase-free DNase I (Takara). RNA concentration was determined by spectrophotometry at 260 nm. The absence of residual DNA in the total RNA digested by DNase I was confirmed by PCR. Reverse transcription was carried out with M-MLV Reverse Transcriptase (Promega) in a 20-µl reaction volume containing 150 ng of random primers and 1 mM dNTP mix (Tiangen Biotech Co. Ltd.) to obtain the cDNA for gene-expression assays with specific primers (Table 2).

Total protein was isolated from HT-29 cells using cell lysis buffer for western blots (Biyuntian Biotech). The cells were treated with cell lysis buffer for 30 min, and then transferred, using a cell scraper, into a 1.5-ml tube. The cells were disrupted by ultrasonication (9 s, two times), centrifuged, and the supernatants were subjected to western blotting.

**Detection of the expression of MMP-9 and phosphor-Erk**

(1/2)

Detect the expression of MMP-9 and phosphor-Erk (1/2). HT-29 cells were separately treated with the expressed KiSS1 (L. lactis NZ9000-401-kiss1) and the KiSS1 plus kisspeptin 234 (300 nM for 2 h). The kisspeptin 234 trifluoroacetate salt, a GPR54 inhibitor, was purchased from Santa Cruz Biotechnologies Inc., (Santa Cruz, CA, USA). Anti-MMP-9 XP rabbit monoclonal antibody (Cell Signaling Technology), phosphor-Erk (1/2) MAPK mouse monoclonal antibody and GAPDH mouse monoclonal antibody (Biyuntian Biotech) were used for detecting the expression of MMP-9, phosphor-Erk (1/2) and GAPDH (used as control), respectively, according to standard Western blot procedures.
Statistical analysis
Statistical analyses were performed using unpaired two-tailed Student’s t test. P values less than 0.05 were considered to be statistically significant. Data are presented as mean ± SEM of three independent repeats in each experiment. Data were analyzed using the SPSS software (Release 17, SPSS Inc., Chicago, IL, USA).

Abbreviations
LAB: lactic acid bacteria; DMEM: Dulbecco’s Modified Eagle medium; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide; MMP-9: matrix metalloproteinase 9; NICE system: nisin-controlled gene expression system; KPS4: kispeptin-S4; ELISA: enzyme-linked immunosorbent assay; GPR54: G-protein coupled receptor 54; iB2: inflammatory bowel disease; GLP-1: glucagon like peptide-1; cDNA: complementary DNA; MMPs: matrix metalloproteinases; GM17: glucose-M17; BSA: bovine serum albumin; TMB: 3, 3′, 5, 5′, 2, 2′-tetramethylbenzidine.

Authors’ contributions
BZ and SC designed and conceived the experiments. FZ constructed the vector BZ, AL, RY and ZZ performed the experiments. BZ analyzed the data and wrote the manuscript. HM and SC reviewed the manuscript. All authors read and approved the final manuscript.

Author details
1 Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, No. 17 Qinghua East Road, Haidian District, Beijing 100083, People’s Republic of China. 2 Key Laboratory of Functional Dairy, Department of Food Science and Engineering, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, People’s Republic of China. 3 College of Horticulture, China Agricultural University, Beijing 100193, People’s Republic of China.

Availability of data and material
The data supporting our findings can be found in the main paper.

Acknowledgements
None.

Competing interests
The authors declare that they have no competing interests.

Funding
This work was supported by the ‘Five-twelfth’ National Science and Technology Support Program of China (20111AA100903).

Received: 23 February 2016 Accepted: 1 June 2016
Published online: 10 June 2016

References
1. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11:905–10.
2. Araújo F, Fonte P, Santos HA, Sarmento B. Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? J Diabetes Sci Technol. 2012;6:1486–97.
3. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today. 2003;8:259–66.
4. Win KY, Feng S-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713–22.
5. Sani I, Abdullahmed A, Bello F. Oral protein-drug delivery systems suitable for systemic circulation. Int J Modern Biol Med. 2014;5:5–16.
6. Wyszyńska A, Kobierceka P, Bardowski J, Jaguszyn-Krynica EK. Lactic acid bacteria—20 years exploring their potential as live vectors for mucosal vaccination. Appl Microbiol Biotechnol. 2015;99:2967–77.
7. Varma NRS, Toosa H, Foo HL, Altheen NBM, Nor Shamsuddin M, Arbab AS, Yusoff K, Abdul Rahim R. Display of the viral epitopes on Lactococcus lactis: a model for food grade vaccine against EV71. Biotechnol Res Int. 2013;2013:431315.
8. Mierau I, Kleenebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol. 2005;68:705–17.
9. Desmond C, Fitzgerald G, Stanton C, Ross P. Improved stress tolerance of GroESL-overproducing Lactococcus lactis and probiotic Lactobacillus paracasei NFBc 338. Appl Environ Microbiol. 2004;70:5929–36.
10. Benbouziane B, Ribelles P, Aubry C, Martin R, Kharat P, Riazi A, Langella P, Bermudez-Humaran LG. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol. 2013;168:120–9.
11. Liang X, Zhang L, Zhong J, Huan L. Secretory expression of a heterologous nattokinase in Lactococcus lactis. Appl Microbiol Biotechnol. 2007;75:95–101.
12. Shigemori S, Yonekura S, Sato T, Nakanishi M, Otani H, Shimosato T. Expression of a biologically active GGF-αS1-casein fusion protein in Lactococcus lactis. Curr Microbiol. 2012;64:569–75.
13. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Renaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L A. Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:754–9.
14. Cano-Garrido O, Seras-Franjoso J, Garcia-Fruttos E. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact. 2015;14:137.
15. Ng DT, Sarkar CA. Nisin-inducible secretion of a biologically active single-chain insulin analog by Lactococcus lactis NZ9000. Biotechnol Biobeng. 2011;108:1987–96.
16. Hunter KW, Crawford N, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10:52.
17. Lee J-H, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88:1731–7.
18. Shirasaki F, Takata M, Hatta N, Takehara K. Loss of expression of the metastasis suppressor gene KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88:1731–7.
19. Ringel MD, Hardy E, Bernier VJ, Burch HB, Schuppert FD, Burman KD, Saji M. Metastasin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J Clin Endocrinol Metab. 2002;87:2399.
20. Sanchez-Carbayo M, Capodici P, Gordon-Cardo C. Tumor suppressor role of KISS1 in bladder cancer: loss of KISS1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol. 2003;162:742–5.
21. Dhar DK, Naora H, Kubota H, Maruyama Y, Yoshimura H, Tomonoto Y, Tachibana M, Ono T, Otani H, Nagasue Y. Downregulation of KISS1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. Int J Cancer. 2004;107:1139–49.
22. Ikeuchi M, Yamaguchi K-I, Kaibara N. Clinical Significance of the Loss of KISS-1 and orphan G-protein-coupled receptor (OT77/175) gene expression in esophageal squamous cell carcinoma. Clin Cancer Res. 2004;10:1379–83.
23. Moya P, Esteban S, Fernandez-Suarez A, Maestro M, Morente M, Sanchez-Carbayo M. KISS-1 methylation and protein expression patterns contrib-ute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer. Tumor Biol. 2013;34:471–9.
24. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Horii A, Kanehashi K, Terao Y, Kumanosato T, Takatsu Y, Masuda Y. Metastasis suppressor gene KISS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411:613–7.
25. Cho SG, Li D, Stafford LJ, Luo J, Rodriguez-Villanueva M, Wang Y, Liu M. KISS1 suppresses TNFa-induced breast cancer cell invasion via an inhibition of RhoA-Mediated NF-kB activation. J Cell Biochem. 2009;107:1139–49.
26. Stathaki M, Armakolas A, Dimakakos A, Kaklamani V, Vlachos I, Konstantoulakis NW, Zografos G, Koutsilieris M. Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients. Mol Med. 2014;20:80.

27. Matsui H, Takatsu Y, Kumano S, Matsumoto H, Ohtaki T. Peripheral administration of metastin induces marked gonadotropin release and ovulation in the rat. Biochem Biophys Res Commun. 2004;320:383–8.

28. Lee J-H, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KISS-1. Cancer Res. 1997;57:2384–7.

29. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.

30. Ji K, Ye L, Ruge F, Hargest R, Mason MD, Jiang WG. Implication of metastasis suppressor gene, Kiss-1 and its receptor Kiss-1R in colorectal cancer. BMC Cancer. 2014;14:1.

31. Nash KT, Welch DR. The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci. 2006;11:647.

32. Gorbach SL. Lactic acid bacteria and human health. Ann Med. 1990;22:37–41.

33. Hirayama K, Rafer J. The role of lactic acid bacteria in colon cancer prevention: mechanistic considerations. Antonie Van Leeuwenhoek. 1999;76:391–4.

34. Ruas-Madiedo P, Hugenholtz J, Zoon P. An overview of the functionality of exopolysaccharides produced by lactic acid bacteria. Int Dairy J. 2002;12:163–71.

35. Looijesteijn PJ, Trapet L, de Vries E, Abee T, Hugenholtz J. Physiological function of exopolysaccharides produced by Lactococcus lactis. Int J Food Microbiol. 2001;64:71–80.

36. Olbrich T, Ziegler E, Turk G, Schubert A, Ermons G, Gründker C. Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: evidence for a dose–window effect. Gynecol Oncol. 2010;119:571–8.

37. Schmidt E, Haase M, Ziegler E, Ermons G, Gründker C. Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells. Int J Gynecol Cancer. 2014;24:210–7.

38. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012;1825:29–36.

39. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.

40. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteinases. Amino Acids. 2011;41:271–90.

41. Giannelli G, Falk-Marzillier J, Schiraldi O, Stefani-Stevenson W, Quaranta V. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science. 1997;277:225–8.

42. Zhang Y, Tang Y, Li Z, Pan F, Huang K, Xu G. KISS1 inhibits growth and invasion of osteosarcoma cells through inhibition of the MAPK pathway. Eur J Histochem. 2013;57:30.

43. Zheng S, Chang Y, Hodges KB, Sun Y, Ma X, Xue Y, Williamson SR, Lopez-Beltran A, Montroni R, Cheng L. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res. 2010;30:713–8.

44. Lee KH, Kim J-R. Kiss-1 suppresses MMP-9 expression by activating p38 MAP kinase in human stomach cancer. Oncol Res Fetal Preclin Clin Cancer Ther. 2009;18:107–16.

45. Yan C, Wang H, Boyd DD. KISS1 represses 92-kDa type IV collagenase expression by down-regulating NF-κB binding to the promoter as a consequence of IκBα-induced block of p65/p50 nuclear translocation. J Biol Chem. 2001;276:1164–72.

46. Kupers OR, de Ruyter PG, Kleerebezem M, de Vos WM. Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol. 1998;64:15–21.

47. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. New York: Cold spring harbor laboratory press; 1989.

48. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Meth Mol Biol. 2001;731:237–45.

49. Chen H-J, Jiang Y-L, Lin C-M, Tsai S-C, Peng S-F, Fushiya S, Hour M-J, Yang J-S. Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells. Int J Oncol. 2013;43:141–50.